Kazia Therapeutics Ltd · NASDAQ:KZIA
Kazia Therapeutics — Gold Coast Investment Showcase 2019
20 slides from Kazia Therapeutics's conference presentation, Jun 25, 2019
Slide 1: Presentation to Gold Coast Investment Showcase
A company developing innovative, high-impact drugs for cancer Presentation to Gold Coast Investment Showcase Surfers Paradise, QLD 25 June 2019 ASX: KZA | NASDAQ : KZIA | Twitter: @KaziaTxA company developing innovative, high-impact drugs for cancer Presentation to Gold Coast Investment Showcase Sur
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of the “safe- harbor” provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve known and unknown risks, uncertainties and other factors that could cause the actual
Slide 3: Reasons to invest in Kazia
Reasons to invest in Kazia We are primarily targeting brain cancer, a disease affecting hundreds of thousands of patients each year, representing a multi-billion dollar market, 1 and with almost no effective treatments available Our lead program, GDC-0084, was designed by Genentech, the world’s most
Slide 4: Treatment of brain cancer has improved little in recent decades
Treatment of brain cancer has improved little in recent decades, unlike other cancers Brain 1990s 2000s 2010s Cancer (glioblastoma) Lung 1990s 2000s 2010s Cancer 3Treatment of brain cancer has improved little in recent decades, unlike other cancers Brain 1990s 2000s 2010s Cancer (glioblastoma) Lung
Slide 5: Kazia has built a program of clinical trials around GDC-0084
Kazia has built a program of clinical trials around GDC-0084 covering the full range of brain cancers GDC-0084 Primary Brain Cancer Secondary Brain Cancer Brain cancer that begins in the brain Brain cancer that spreads from elsewhere in the body Glioblastoma (GBM) DIPG Brain Metastases Breast Cancer
Slide 6: Kazia has been delivering all milestones on schedule
Kazia has been delivering all milestones on schedule, with key data read-outs remaining in 2H 2019 ✓✓✓ ✓✓ Data read-out Receipt of Commence Commence Data read-out GDC-0084 Start of phase from phase 2a Orphan Drug collaborations collaboration from phase 2a 2a study in study Designation in DIPG and st
Slide 7: Glioblastoma is the most common and aggressive primary brain cancer
Glioblastoma (GBM) is the most common and most aggressive form of primary brain cancer Lung 12-15 No clear 3-4 months months cause untreated Breast survival average or strong risk 14 million survival with factors cancer cases treatment per annum Colon Any age, Five-year but most survival Prostate co
Slide 8: Current treatment is ineffective in approximately 65% of GBM cases
Current treatment is essentially ineffective in approximately 65% of GBM cases ~35% of patients respond to temozolomide Extends overall survival from Temozolomide is the only 15 to 22 months FDA-approved drug for newly-diagnosed patients ~65% of patients don’t respond to temozolomide Extends overall
Slide 9: GDC-0084 works by switching off PI3K
GDC-0084 works by switching off PI3K, a critical control mechanism that drives many types of cancer PI3K ACTIVATED 85 – 90% of glioblastoma cases TUMOUR have PI3K ‘switched on’ GROWTH PI3K A central biochemical control PI3K INHIBITED mechanism in the growth of cells TUMOUR GDC-0084 switches off PI3K
Slide 10: GDC-0084 is able to cross the blood-brain barrier
GDC-0084 is the only drug of its kind that is able to cross the ‘blood-brain barrier’ (BBB) Most drugs cannot reach disease in the brain GDC-0084 crosses the BBB The ‘blood-brain barrier’ prevents most drugs from GDC-0084 was specifically designed for brain cancer, and getting into the brain, render
Slide 11: Phase 1 trial of GDC-0084 showed favourable safety and efficacy signals
A phase 1 human trial of GDC-0084 showed favourable safety and multiple efficacy signals Safety Efficacy Signals • Phase I safety trial conducted by GDC-0084 Comparison Genentech 40% 21-52% • 47 patients enrolled with advanced Arresting Achieved in studies of glioma (grade 3/4); average of Tumour Gr
Slide 12: In the phase 1 trial, 7/27 patients showed a response
In the GDC-0084 phase 1 trial, 7 / 27 patients (26%) showed a response to drug* Pre-Dosing On GDC-0084 Pre-Dosing On GDC-0084 * Metabolic partial response per FDG-PET Analysis courtesy of Professor Ben Ellingson, UCLA Brain Tumor Imaging Laboratory 11In the GDC-0084 phase 1 trial, 7 / 27 patients (2
Slide 13: Alliance study in brain metastases is a multi-drug clinical trial
The recently-announced Alliance study in brain metastases is a cutting-edge, multi-drug clinical trial 150 patients Funded by abemaciclib US National Cancer Institute Secondary brain cancer Tumour is from any genetically GDC-0084 primary profiled Executed by Alliance for Clinical tumour Trials in On
Slide 14: Brain cancer is a significant commercial opportunity for GDC-0084
INDICATIVE Brain cancer represents a significant commercial opportunity for GDC-0084, with limited competition Path to Market Expansion Opportunities ‘Blue Sky’ Potential Brain Metastases Glioblastoma (secondary brain cancer) Other Adult Other Cancers with Primary Brain Disordered PI3K 12,500 Cancer
Slide 15: Cantrixil program in ovarian cancer showing positive results
Cantrixil program in ovarian cancer has been showing positive results; further data expected 2H19 October 2017 (baseline) January 2018 Source: images courtesy of Professor Jim Coward, Icon Cancer Centre 14Cantrixil program in ovarian cancer has been showing positive results; further data expected 2H
Slide 16: Kazia is NASDAQ & ASX listed
Kazia is NASDAQ & ASX listed Share Price (AU$) KZA 0.60 Current Assets (Dec 18) Debt AU$ 11.6 million Nil Market Capitalisation AU$ 22 million 0.50 NASDAQ: KZIA (1:10 ratio) Listing ASX: KZA 0.40 NASDAQ: 0.2% /day Average Daily Volume ASX: 0.1% /day NASDAQ: US$ 21K /day Average Daily Value ASX: AU$
Slide 17: A strong team brings international experience
A strong team brings international experience in big pharma and early-stage biotech Board Scientific Advisory Board Iain Ross Professor Sir Murray Brennan Chairman Emeritus Chairman of Cancer Surgery at Memorial Sloan Kettering Hospital, New York Executive and Board roles in pharma and small biotech
Slide 18: Other PI3K-focused companies have been highly valued
Other companies focused on the PI3K pathway have been highly-valued in the market Single asset company with one PI3K US$ 90 million inhibitor in phase I human trials Market Cap One PI3K inhibitor in phase II human US$ 620 million trials, one other drug in phase III, and Market Cap two in animal test
Slide 19: Reasons to invest in Kazia
Reasons to invest in Kazia We are primarily targeting brain cancer, a disease affecting hundreds of thousands of patients each year, representing a multi-billion dollar market, 1 and with almost no effective treatments available Our lead program, GDC-0084, was designed by Genentech, the world’s most
Slide 20: www.kaziatherapeutics.com
www.kaziatherapeutics.comwww.kaziatherapeutics.com
Kazia Therapeutics — Gold Coast Investment Showcase 2019 on 6ix